MT has received one Phase I SBIR funding for feasibility study of this project in July, 2015. MT also has one pending application of Ohio Third Frontier Technology Validation and Start-Up Fund ($150,000). MT has also reached a finance agreement with Rudong High-Tech Venture Investment Co. of Jiangsu Provence, China, to support the preclinical evaluation and phase 1 clinical trial of the targeted contrast agent contingent on the success of obtaining funding from other sources, including this Phase II grant application. The initial agreed fund is RMB15,000,000 Yuan, approximately $2.3 million. MT will approach series A venture capital firms during the execution of the eIND study. MT is currently negotiating with the CAO group located at West Jordan, UT for licensing the MT’s tumor detection, imaging, and localization technology.